(Q34068757)

30 July 2017

Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome (English)

1 reference

30 July 2017

1 reference

Kanako Bokuda

1

1 reference

30 July 2017

Atsuhiro Ichihara

2

1 reference

30 July 2017

Mariyo Sakoda

3

1 reference

30 July 2017

Asako Mito

4

1 reference

30 July 2017

Kenichiro Kinouchi

5

1 reference

30 July 2017

Hiroshi Itoh

6

1 reference

30 July 2017

language of work or name

English

0 references

publication date

9 August 2010

1 reference

Vascular Health and Risk Management

30 July 2017

1 reference

30 July 2017

6

1 reference

30 July 2017

571-578

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

30 July 2017

start time

1 July 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Usefulness of RAS inhibition depends on baseline albuminuria.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Vascular and metabolic effects of candesartan: insights from therapeutic interventions.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Evaluation of subclinical organ damage for risk assessment and treatment in the hypertensive patient: role of microalbuminuria

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Cardiovascular morbidity and mortality associated with the metabolic syndrome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2922318

1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee

28 October 2018

1 reference

12 December 2020

Benefits of candesartan on arterial and renal damage of non-diabetic hypertensive patients treated with calcium channel blockers

1 reference

12 December 2020

Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men

1 reference

12 December 2020

Cardio-ankle vascular index and ankle pulse wave velocity as a marker of arterial fibrosis in kidney failure treated by hemodialysis

1 reference

12 December 2020

Identifiers

DOI

10.2147/VHRM.S11958

1 reference

30 July 2017

1 reference

30 July 2017

1 reference